MEIZHIGAO
834765
Shanghai Electric Wind Power Group
688660
Suzhou Longway Electronic Machinery
301202
HFZS
839725
KAITIANGAS
831010
CN Stock MarketDetailed Quotes
002022 Shanghai Kehua Bio-engineering
- 6.31
- -0.30-4.54%
Market Closed Dec 31 15:00 CST
3.25BMarket Cap-9.65P/E (TTM)
6.71High6.30Low139.81KlotVolume6.65Open6.61Pre Close90.26MTurnover2.72%Turnover RatioLossP/E (Static)514.32MShares10.3852wk High0.84P/B3.24BFloat Cap5.0552wk Low7.27Limit Up514.24MShs Float62.49Historical High5.95Limit Down6.20%Amplitude-1.78Historical Low--Dividend TTM6.46Avg Price75.74KlotAsk--Div YieldTTM100Lot Size61.89KlotBid
Shanghai Kehua Bio-engineering News
Shanghai Kehua Bio-engineering (002022.SZ) has been approved by the National Medical Products Administration: new test kit for Helicobacter pylori antibody detection.
On January 1, Gelonghui reported that Shanghai Kehua Bio-engineering (002022.SZ) announced that it recently received the medical instruments registration certificate issued by the National Medical Products Administration (in vitro diagnostic reagents). The specific product is "Helicobacter pylori antibody detection kit (latex immunoturbidimetry method)", with registration certificate number National Medical Device Approval 20243402655, valid from December 30, 2024, to December 29, 2029. This product is used for the qualitative detection of Helicobacter pylori antibodies in human serum and plasma samples.
Shanghai Kehua Bio-EngineeringLtd (SZSE:002022 Shareholders Incur Further Losses as Stock Declines 11% This Week, Taking Three-year Losses to 55%
Kehua Tech Recognized in BNEF's Latest Bankability Survey
Kehua Ranked No.4 in the Global Modular UPS Market Share for Two Consecutive Years
Shanghai Kehua Bio-Engineering, Subsidiaries to Invest 68 Million Yuan for New Unit
Shanghai Kehua Bio-engineering (002022.SZ) plans to establish a subsidiary to undertake the Shaanxi Province High-Performance Diagnostic Medical Instruments Innovation Center project.
Shanghai Kehua Bio-engineering (002022.SZ) has announced the undertaking of the Shaanxi Province High-Performance Diagnostic Medical Instruments Innovation Center project...
shanghai kehua bio-engineering (002022.SZ): not involved in chip R&D business
Shanghai Kehua Bio-engineering (002022.SZ) stated on the investor interaction platform on November 28 that the company's main business is the research and development, production, and sales of in vitro diagnostic reagents and medical testing instruments. The company is not involved in chip business.
Kehua Bio-Engineering Gets Device Registration Certificate for Creatine Kit
Shanghai Kehua Bio-Engineering (002022.SZ): Creatine Kinase Isoenzyme Assay Kit obtained the registration certificate for medical instruments.
Shanghai kehua bio-engineering (002022.SZ) stated on the investor interaction platform today that the company recently obtained a medical device registration certificate (in vitro diagnostic reagent) issued by the Shanghai Municipal Food and Drug Administration. The product is named Creatine Kinase Isoenzyme Assay Kit (Latex Immunoassay), this assay kit is supplied to medical institutions for the quantitative determination of creatine kinase isoenzyme in human serum or plasma samples, clinically used for the auxiliary diagnosis of diseases such as myocardial infarction and myopathy.
shanghai kehua bio-engineering (002022.SZ): The company sells products in Saudi Arabia.
On November 7th, shanghai kehua bio-engineering (002022.SZ) stated on the investor interaction platform that the company sells products in Saudi Arabia, currently on a small scale. The company will continue to consolidate its existing overseas customer network and actively expand overseas markets.
Kehua Biotech: Report for the third quarter of 2024
shanghai kehua bio-engineering (002022.SZ): a net loss of 69.6766 million yuan in the third quarter.
On October 21st,2024, shanghai kehua bio-engineering (002022.SZ) announced its third quarter report. In the third quarter of 2024, the company achieved revenue of 0.442 billion yuan, a year-on-year decrease of 13.01%; net income attributable to shareholders of the listed company was a loss of 69.6766 million yuan, a year-on-year decrease of 69.60%; net income after deducting non-recurring gains and losses was a loss of 70.3352 million yuan, a year-on-year decrease of 57.25%; basic earnings per share was a loss of 0.1378 yuan per share.
shanghai kehua bio-engineering (002022.SZ) released its performance for the first three quarters, with a net loss of 0.122 billion yuan
Shanghai Kehua Bio-engineering (002022.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Investors Don't See Light At End Of Shanghai Kehua Bio-Engineering Co.,Ltd's (SZSE:002022) Tunnel
Kehua Tech Ranked No. 1 in China and No. 3 Worldwide for Energy Storage Inverter Market Share
shanghai kehua bio-engineering (002022.SZ): has repurchased 2.47% of the shares accumulated.
shanghai kehua bio-engineering (002022.SZ) announced on October 8th that, as of September 30, 2024, the company has cumulatively repurchased 12,688,300 shares of the company through a special securities account for repurchasing shares by centralized bidding trading method, accounting for 2.47% of the current total share capital of the company. The highest fill price for the repurchase was 10.68 yuan/share, and the lowest fill price was 5.10 yuan/share, with a total fill amount of 94,211,045.71 yuan (excluding transaction costs). This repurchase is in compliance with relevant laws and regulations and the requirements of the company's share repurchase program.
shanghai kehua bio-engineering (002022.SZ): The holding subsidiary's real-time fluorescence PCR analyzer has obtained the medical instruments registration certificate
On September 24, Kelunhui announced that its subsidiary Xi'an Tianlong Technology Co., Ltd. received the medical devices registration certificate issued by the National Medical Products Administration, with the product name as Real-time Fluorescent PCR Analyzer. The product is based on the principle of real-time fluorescent PCR detection and is used in conjunction with supporting test reagents for qualitative and quantitative detection of target nucleic acids (DNA/RNA) from human samples in clinical settings, including pathogen and human gene detection projects.
Shanghai Kehua Bio-Engineering (002022.SZ): The KHB Nova 9600 fully automated sample handling system is aimed at clinical laboratories performing tandem mass spectrometry testing.
Shanghai Kehua Bio-engineering (002022.SZ) announced that the company's KHB Nova 9600 fully automated sample processing system is aimed at clinical laboratories conducting tandem mass spectrometry testing. It can be used in conjunction with the company's tandem mass spectrometry reagents and is widely used in testing projects such as vitamin detection, drug concentration monitoring, catecholamine and its metabolite detection, and corticosteroid detection. Compared with traditional manual operations, it can provide customers with a one-stop automated mass spectrometry pre-processing solution.
Shanghai Kehua Bio-Engineering (002022.SZ) has accumulated a repurchase of 2.29% of the shares, costing approximately 89.213 million yuan.
Shanghai Kehua Bio-Engineering (002022.SZ) announced that as of August 31, 2024, the company has cumulatively repurchased its shares...
Kehua Biotech: 2024 Semi-Annual Report
